Clinical aspects of systemic and localized scleroderma

Area of Science:

• Rheumatology
• Immunology
• Dermatology

Background:

• Scleroderma's clinical course, subsets, and outcomes require better definition.
• Understanding disease progression and identifying predictive factors are crucial for patient management.

Purpose of the Study:

• To elucidate the triphasic nature of scleroderma skin involvement.
• To investigate the predictive value of autoantibodies for disease course.
• To highlight key organ involvements and their management implications.

Main Methods:

• Analysis of clinical data to define disease phases.
• Serological testing for autoantibodies, including anti-polymerase I, II, and III.
• Evaluation of organ-specific manifestations (lung, kidney, gastrointestinal, microvasculature).
• Assessment of psychosocial impacts and disease etiology.

Main Results:

• Scleroderma skin thickening is most active in the first 12 months.
• Anti-polymerase antibodies are specific to scleroderma and may predict aggressive disease.
• Early lung involvement detection aids treatment selection; renal crisis can occur without significant skin fibrosis.
• Gastrointestinal reflux and microvascular abnormalities are common.
• Depression and social support needs are significant psychosocial factors.

Conclusions:

• Autoantibodies, particularly anti-polymerase, are valuable predictors of scleroderma's clinical trajectory.
• Comprehensive assessment of organ involvement and psychosocial well-being is essential for managing scleroderma.
• The etiology of localized scleroderma remains undetermined.